Efficacy and Safety of Ningmitai Capsules in Patients with Chronic Epididymitis: A Prospective, Parallel Randomized Controlled Clinical Trial

Table 4

Evaluation of hepatorenal function after 4 weeks of treatment.

	LVX	NMT	LVX + NMT	Reference range
n	36	40	36
ALT (U·L^−1)
V0	29.94 ± 13.667	28.33 ± 10.406	32.72 ± 11.609	9∼50
V2	32.33 ± 12.205	31.88 ± 8.762	32.94 ± 10.559
BUN (mmol·L^−1)
V0	4.78 ± 1.104	4.97 ± 0.933	5.43 ± 1.072	2.8∼7.14
V2	4.77 ± 1.072	5.13 ± 1.145	5.46 ± 1.065
CREA (μmol·L^−1)
V0	71.39 ± 20.080	69.50 ± 20.796	78.72 ± 20.928	40∼135
V2	72.03 ± 21.856	61.30 ± 17.164	81.98 ± 19.655

LVX, levofloxacin; NMT, Ningmitai; ALT, alanine aminotransferase; BUN, blood urea nitrogen; CREA, creatinine.